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The traditional view of hematopoiesis has been that
all the cells of the peripheral blood are the progeny
of a unitary homogeneous pool of hematopoietic
stem cells (HSCs). Recent evidence suggests that
the hematopoietic system is actually maintained by
aconsortiumofHSCsubtypeswithdistinct functional
characteristics. We show here that myeloid-biased
HSCs (My-HSCs) and lymphoid-biased HSCs (Ly-
HSCs) can be purified according to their capacity
for Hoechst dye efflux in combination with canonical
HSC markers. These phenotypes are stable under
natural (aging) or artificial (serial transplantation)
stress and are exacerbated in the presence of
competing HSCs. My- and Ly-HSCs respond differ-
ently to TGF-b1, presenting a possible mechanism
for differential regulation of HSC subtype activation.
This study demonstrates definitive isolation of
lineage-biased HSC subtypes and contributes to
the fundamental change in view that the hematopoi-
etic system is maintained by a continuum of HSC
subtypes, rather than a functionally uniform pool.
INTRODUCTION
Multipotent long-term HSCs (LT-HSCs) reside in the bone
marrow and self-renew to sustain the stem cell pool and differen-
tiate into short-term HSCs (ST-HSCs) or lineage-restricted
progenitors that undergo extensive proliferation and differentia-
tion to produce terminally differentiated hematopoietic cells.
Although various methods are used for HSC purification (Challen
et al., 2009), ultimately, HSCs are defined not by phenotype, but
by function in terms of hematopoietic reconstitution in bone
marrow transplantation assays (Szilvassy et al., 1990; Span-
grude et al., 1995). LT-HSCs can be operationally defined by
the ability to contribute to more than 1% of circulating white
blood cells long-term (>16 weeks) after transplantation, with
generation of myeloid and lymphoid progeny at levels >1% as
an indicator of extensive self-renewal ability (Miller and Eaves,
1997; Ema et al., 2005; Dykstra et al., 2006). Since HSCs werefirst identified, the traditional view has been that the hematopoi-
etic system is regenerated by a single pool of quiescent
LT-HSCs that are recruited as needed. However, HSCs show
heterogeneous behavior at the clonal level (Lemischka et al.,
1986; Jordan and Lemischka, 1990; Smith et al., 1991), and
recent studies suggest that the adult HSC compartment consists
of a number of functionally distinct subsets with distinct
self-renewal and differentiation potentials (Dykstra et al., 2007;
Sieburg et al., 2006; Wilson et al., 2008).
By serial transplantation of single HSCs and their progeny,
Dykstra et al. demonstrated that HSC activity could be classi-
fied by four behaviors according to their lineage differentiation
capacity as well as the length of time over which they could
contribute to high levels of blood production (Dykstra et al.,
2007). Another group proposed three classes of HSCs based
on repopulation kinetics of mice transplanted with limiting
dilutions of whole bone marrow—myeloid-biased (My-bi), lym-
phoid-biased (Ly-bi), and balanced HSCs (Bala)—that gener-
ated myeloid and lymphoid cells in the same ratio as seen in
the blood of unmanipulated mice (Mu¨ller-Sieburg et al., 2002;
Muller-Sieburg et al., 2004; Sieburg et al., 2006). The behaviors
of HSC subtypes are relatively stable over long periods in vivo,
but are rapidly eroded in vitro (Wineman et al., 1996; Lemieux
and Eaves, 1996). Although these studies provide evidence
for the existence of HSC subpopulations in terms of their
functional properties, further understanding of the molecular
mechanisms that empower each subset with their distinctive
characteristics is impeded by a lack of approaches for their
facile purification.
Our laboratory typically uses Hoechst 33342 staining to iden-
tify HSCs, which reside in the so-called side population (SP)
(Goodell et al., 1996). Although cells within the SP are very
similar in terms of expression of canonical stem cell markers,
it has been shown that cells from different regions of the SP
possess different functional potentials, particularly over long
periods of time (Goodell et al., 1997; Camargo et al., 2006).
We recently reported heterogeneous expression of the sig-
naling lymphocytic activation molecule (SLAM) family molecule
CD150 within the SP, with CD150+ cells more prevalent in the
lower SP (Weksberg et al., 2008), suggesting that this marker
may help delineate HSC subtypes. This is consistent with the
finding that CD150+ HSCs exhibit the highest long-term HSC
activity correlating with persistent myelopoiesis (Kent et al.,
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Figure 1. Phenotypes of SP Subtypes
Left column shows surface marker HSC identification strategy
from whole bone marrow based on lineage-negative, c-kit,
Scal-1 expression, as well as Flk-2 and CD34. Top middle panel
demonstrates delineation of SP. Top right shows regions desig-
nated as lower SP and upper SP and below that, c-kit and Sca-1
cells expression of cells gated on these and through a lineage-
negative gate. Surface markers on these cells, designated as
SPKLS, are shown below. CD150 expression is heterogeneous,
with CD150+ cells more prevalent in the lower SP (see also
Figure S1).
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homogeneous HSCs, we sought to determine whether Hoechst
dye efflux could be used to discriminate different HSC sub-
types. We demonstrate that lineage-biased HSCs can be
prospectively isolated according to their capacity for dye efflux
with further augmentation of this purification strategy via selec-
tion with CD150. By using the combination of SP and CD150,
we show a very clear gradient of HSCs with distinct pheno-
typic, functional, and molecular characteristics. We also iden-
tify the TGF-b signaling pathway as a potential mechanism of
differential regulation between HSC subtypes and show that
TGF-b1 exacerbates these functional differences in vitro and
in vivo.266 Cell Stem Cell 6, 265–278, March 5, 2010 ª2010 Elsevier Inc.RESULTS
Phenotypic Diversity of Cells from Different
Regions of the Side Population
We typically purify HSCs by the phenotype of side pop-
ulation+ c-Kit+ Lineage Sca-1+ (Figure S1A available
online; henceforth called SPKLS). The SP contains virtu-
ally all of the long-term HSC activity (Goodell et al.,
1996). Despite similar surface marker staining, there
appears to be a gradient of functional activity along
the SP (Goodell et al., 1997). Flow cytometric analysis
of the regions designated as lower SP and upper SP
(Figure 1) are extremely similar and are essentially
phenotypically indistinguishable from HSCs isolated
via classical schemes (KLS Flk-2 CD34) or newer
markers (EPCR+ CD48), although lower SP cells
have slightly brighter expression of Sca-1 and EPCR
and slightly dimmer expression of Flk-2 and CD34 by
mean fluorescent intensity (Figure S1B). In contrast,
as previously reported (Weksberg et al., 2008),
CD150 shows a bimodal distribution on SPKLS cells,
with the lower SPKLS containing a higher frequency of
CD150+ cells.
Transplanted SP Subfractions Show
Different Hematopoietic Lineage Outputs
We investigated the functional characteristics of HSCs
isolated from different regions of the SP by competitive
transplantation assays, the gold standard for quanti-
fying HSC activity. Competitive transplantations were
performed such that test and recipient cell populations
were distinguishable by combinations of CD45 alleles.
Lethally irradiated recipients were transplanted with200,000 competitor whole bone marrow cells along with either
200 lower SPKLS cells or 200 upper SPKLS cells (Figure 2A). SP
sorting gates were set well apart to minimize cross-contamina-
tion. Peripheral blood was drawn every 4 weeks posttransplant
to monitor donor cell engraftment and lineage distribution
(Figure S2A).
Multiple cohorts of bone marrow transplants experiments
recapitulated previous work demonstrating higher long-term
engraftment of lower SPKLS cells compared to upper SPKLS
(approximately 2.5-fold higher peripheral blood chimerism 16
weeks posttransplant). However, we observed a striking previ-
ously unreported bias in terms of the hematopoietic lineage
output of transplanted SP fractions (Figure 2B). Although both
Figure 2. Repopulation Kinetics of Transplanted SP
Subtypes
(A) Competitive transplant scheme for lower and upper SPKLS cells
individually (200 per recipient) or in combination (100 of each subtype
per recipient), with 200,000 whole bone marrow competitor cells in all
transplants.
(B) Overall peripheral blood contribution (Engraft) and proportional
contribution to myeloid, B, and T cells at 4 and 16 weeks after trans-
plantation of SP fractions into separate mice.
(C) Peripheral blood analysis after transplantation of both upper and
lower SPKLS into the same recipients.
(D) Scheme for repurification of primary HSCs and transplantation into
secondary recipients.
(E) Contribution to the blood of SP subpopulations after secondary
transplantation at 4 and 16 weeks.
(F) Reconstitution of blood in secondary recipients by SP originally
cotransplanted in primary transplants.
Error bars represent SEM. See also Figure S2A.
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Hematopoietic Stem Cell Heterogeneitylower and upper SPKLS cells were capable of forming all hemato-
poietic cell types, lower SPKLS cells were biased toward myeloid
differentiation whereas upper SPKLS cells were biased toward
lymphoid differentiation (B and T cells). At short-term time points
(4 weeks posttransplant), lower SPKLS cells generated signifi-
cantly more myeloid cells (90.4% ± 2.9% versus 77.0% ±
5.2%) whereas upper SPKLS cells produced significantly more
B cells (21.9% ± 5.3% versus 9.9% ± 2.8%). At long-term time
points (16 weeks), lower SPKLS cells retained a higher myeloid
output (20.0% ± 3.3% versus 4.3% ± 1.4%), but upper SPKLS
cells generated significantly more T cells (64.3% ± 6.4% versus
40.4% ± 4.5%) while the B cell output of both populations was
not significantly different. This showed that both populations
have the potential to make all hematopoietic cell types, but
they were inherently biased toward production of a particular
hematopoietic branch.
Cotransplantation of Competing SP Subfractions
Enhances Lineage Biases
We next wondered whether the SP subfractions would behave
differently in the presence of the other subtype. We repeated
the transplantation experiments by cotransplanting 100 lower
SPKLS cells plus 100 upper SPKLS cells in the presence of
200,000 whole bone marrow competitor cells (all distinguishable
by CD45 alleles) into lethally irradiated mice. The lineage biases
observed from transplantation of one SP subfraction alone held
true when the two SP subfractions were cotransplanted into the
same recipient animal; however, the differences were magnified
(Figure 2C). This suggests that although both populations are
capable of forming all hematopoietic lineages, in the presence
of the other HSC subtype (as would be the case in normal phys-
iology), the majority of the output from each HSC subtype is
strongly predisposed toward the differentiation program toward
which they are more inherently inclined.
Lineage Biases of SP Subfractions Are Retained
upon Serial Transplantation
In order to determine whether the hematopoietic outputs of HSC
subtypes was a stable phenotype and to establish bothwere true
HSCs by definition of self-renewal, secondary transplantation of
purified primary HSCs was performed. At >18 weeks posttrans-
plant, donor HSCs from the bone marrow of primary recipients
were repurified (SPKLS + appropriate CD45 allele) and 200 were
transplanted into secondary recipients along with 200,000 fresh
whole bone marrow competitor cells. From primary recipients
that had been cotransplanted with both lower and upper SPKLS
cells, each donor HSC population was isolated and retrans-
planted as individual populations into secondary recipients
(Figure2D). Inall cases, all populationswerestill capableof gener-
ating all lineages in secondary recipients. Notably, the lineage
biases initially observed were recapitulated upon secondary
transfer, with lower SPKLS cells generating more myeloid cells
and upper SPKLS cells producingmore lymphoid cells (Figure 2E).
In the primary transplants that received both HSC subtypes, the
lineage outputwas comparable to secondary recipients receiving
individually transplanted primary lower or upper SPKLS cells
(Figure 2F). In other words, the differentiation biases remained
the same, but were not as extreme as when they had been
competed against purified HSCs of the other subtype.268 Cell Stem Cell 6, 265–278, March 5, 2010 ª2010 Elsevier Inc.These data indicate that both lower SPKLS and upper SPKLS
are bona fide HSCs by definition of long-term, multilineage
reconstitution (generating >1% white blood cells >16 weeks
posttransplant and >1% contribution to both myeloid and
lymphoid branches in primary and secondary recipients).
However, each population has an inherent bias toward genera-
tion of a particular hematopoietic branch that is maintained
over multiple transplant generations. Statistical measures from
all transplantation studies can be found in Table S1.
SP Subtypes Generate Different Proportions
of Lineage-Specific Progenitors
To determine whether the lineage biases observed as mature
hematopoietic cells in the peripheral blood resonated in hemato-
poietic progenitor populations, transplant recipients were
sacrificed after long-term engraftment, and donor cell contribu-
tion to stem and progenitor cell compartments was examined
(Figure 3A). The higher levels of peripheral blood chimerism in
mice transplanted with lower SPKLS cells was reflected in
a greater contribution to recipient LT-HSC (49.6%± 9.7% versus
14.4% ± 8.1%) and MPP (35.4% ± 7.7% versus 20.9% ± 9.3%)
compartments. The lineage biases in the peripheral blood were
propagated from differences to contributions to the earliest
committed progenitors, with donor lower SPKLS cells generating
significantly more myeloid progenitors (MPs; 43.1% ± 7.6%
versus 9.0% ± 4.1%) and upper SPKLS producing more common
lymphoid progenitors (CLPs; 39.5% ± 9.3% versus 20.2% ±
5.3%) in transplanted mice. In mice that were cotransplanted
with both lower and upper SPKLS cells, the biases for lineage-
specific progenitors were the same as for mice transplanted
with individual HSC subtypes, although the differences were
magnified.
Transplanted SP Subfractions Regenerate Themselves
in Recipient Mice
Because the SP appears to allow HSC subtypes to be distin-
guished, we asked whether the HSC subtypes would preferen-
tially repopulate the SP regions from which they were originally
derived in the donor mice. Analysis of the SP profile of recipient
mice, with the appropriate CD45 marker, showed striking
differences in the regional contribution of donor cells to recipient
SP fractions (Figure 3B). Donor lower SPKLS cells tended to
generate more lower SP cells in recipient mice compared to
internal control competitor (63.8% ± 3.0% versus 37.9% ±
3.0%) whereas the converse was true, with donor upper SPKLS
cells generating more upper SP compared to competitor
(48.8% ± 2.3% versus 26.4% ± 1.2%). A much more dramatic
effect was noticed in mice cotransplanted with both SP subfrac-
tions with each cell population strongly biased to regenerate the
same population in the SP of the recipient animals. In cotrans-
planted mice, donor lower SPKLS cells generated the majority
of lower SP cells (72.5% ± 5.3%) whereas donor upper SPKLS
cells almost exclusively generated upper SP cells (95.8% ±
3.8%). In comparison, transplantation of nonfractionated SPKLS
regenerates the SP in the same proportion as whole bone
marrow competitor (Figure S2B). The determination that each
transplanted SP subfraction tended to regenerate itself in the
SP of recipient mice argues that these cell populations exist as
distinct HSC subtypes in the bone marrow, with self-renewal to
Figure 3. Donor-Derived Contribution to
Stem and Progenitor Cell Compartments
of Transplant Recipients
(A and B) Analysis of the bone marrow of recipient
mice to determine donor cell contribution to stem
and progenitor cell compartments 18 weeks post-
transplant of SP subtypes transplanted separately
(A) and into the same recipients (B).
(C) Analysis of the donor cell contribution to SP of
recipient mice. In reference to the whole bone
marrow competitor cells that serve as an internal
control, each SP subfraction tended to regenerate
itself. Data presented are averages of three sepa-
rate pooled experiments.
Error bars represent SEM. See also Figure S2B.
Cell Stem Cell
Hematopoietic Stem Cell Heterogeneitygenerate daughter HSCs that maintain the inherent properties of
the parent.
CD150 Expression Augments the Discrimination
of Lineage-Biased HSCs
To ensure that the results described above were attributable to
inherent differences in HSCs, and not simply impurities in the iso-
lated populations, we repeated these experiments with single
purified HSCs. Single lower or upper SPKLS HSCs were cotrans-
planted into lethally irradiated recipient mice along with 1 3 106
compromised (once-transplanted) whole bone marrow com-
petitor cells; stable long-term engraftment was defined as at
least 0.1% white blood cell contribution from test donor cells
with trilineage contribution from donor-derived cells minimally
at >1%myeloid, B, andTcells >12weeksposttransplant. In three
separate cohorts of single-cell transplant experiments, the
lineage biases observed with the bulk HSCs were evident and
accentuated. Short times after transplant (4 weeks), single lower
SPKLS cells predominantly generated myeloid cells, whereasCell Stem Cell 6, 265–2upper SPKLS cells were muchmore effec-
tive at generating B cells (Figure S3A)
(T cell development typically lags behind
that of B and myeloid cells). 12 weeks
after transplantation, clones from both
regions effectively generated all three
lineages, but with pronounced myeloid
and lymphoid biases for the lower SPKLS
andupperSPKLS, respectively (Figure4A).
The frequency of functional HSC, as
measured by the proportion of mice
successfully engrafted with a single HSC
and showing trilineage contribution at 12
weeks after transplantation, was 27.7%
in the lower SPKLS fraction (18 positive/
65 transplanted mice) and 19.7% in the
upper SPKLS (15 positive/76 transplanted
mice). This is comparable to that reported
for other highly purified populations
(Uchida et al., 2003; Matsuzaki et al.,
2004; Takano et al., 2004; Camargo
et al., 2006; Kiel et al., 2009).
Given the recent evidence for CD150
expression correlating with HSC self-renewal (Kiel et al., 2005; Kent et al., 2009) and our report
showing heterogeneous expression of CD150 in the SP (Weks-
berg et al., 2008), we repeated single-cell transplants with lower
or upper SPKLS HSCs that were further subfractionated on the
basis of CD150 expression. The results paralleled the above
findings with some subtle differences. Short-term posttrans-
plant, CD150 lower SPKLS showed a marginal improvement in
T cell generation compared to their CD150+ counterparts, at
the expense of myeloid cell production. Similarly, CD150+ upper
SPKLS showed, on average, enhanced myeloid cell production
relative to CD150 upper SPKLS (Figure S3B). Long-term post-
transplant (>12 weeks), both CD150+ lower and upper SPKLS
cells showed a greater propensity for myeloid cell production
than their CD150 counterparts (Figure 4B). However, the effect
of CD150 subfractionation was incremental compared to selec-
tion on the basis of Hoechst dye efflux, as shown by the fact that
both CD150+ andCD150 lower SPKLS HSCsweremoremyeloid
biased than upper SPKLS, irrespective of their CD150 status.
Worth noting is the considerable degree of heterogeneity in78, March 5, 2010 ª2010 Elsevier Inc. 269
Figure 4. Clonal Analysis of HSC Subtypes via Single-Cell Transplantation
(A) Tracking of eight individual lower and upper SPKLS clones showing overall hematopoietic chimerism in recipient mice (engraftment; top panels in gray) and
lineage distribution of test cells 12 weeks posttransplant.
(B) Analysis of overall engraftment and lineage contribution of lower and upper SPKLS cells also fractionated with respect to CD150.
(C) Distribution of lineage contribution 12 weeks after transplant from mice transplanted with single HSCs with the indicated phenotypes.
(D) Average level of hematopoietic chimerism from single-cell transplantation experiments.
(E) Lineage contribution measured 12 weeks after secondary transplantation of cells derived from primary mice reconstituted with a single HSC. Bone marrow
from each clone was tested in four new recipients. All clones met the assigned threshold of at least 0.1% overall contribution to all four secondary recipients at
12 weeks posttransplant, with the exception of USP-3, in which 3/4 recipients fell just below the assigned threshold.
Error bars represent SEM. See also Figure S3.
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nated bone marrow cell populations, particularly in long-term
B cell output (Figure 4C). Generally, higher B cell development
at early time points is a harbinger of a lymphoid-biased clone,
whereas high myeloid development heralds a myeloid-biased
HSC; long-term B cell development is generally relatively robust
in both types.
Fractionation of SP subtypes by CD150 expression did not
dramatically alter the HSC frequency in each test population.
We could observe a clear gradient in HSC frequency, with
CD150+ lower SPKLS having the highest HSC frequency (12 posi-
tive/45 transplanted mice; 26.7%), followed by CD150 lower
SPKLS (11/43; 25.6%), CD150+ upper SPKLS (8/41; 19.5%), and
CD150 upper SPKLS (8/43; 18.6%). This is mirrored by a
gradient in their average overall contribution to peripheral blood
generation (Figure 4D). Single-cell transplantation is generally
believed to underestimate the actual frequency of HSCs within
a test population resulting from engraftment dynamics, and
thus the true HSC frequency in these populations may be higher.
It is not possible to determine whether these frequencies repre-
sent inherent limitations in the assay, or remaining heterogene-
ities in the population that additional markers will ultimately allow
us to discern.
To conclusively examine the ability of single lower and upper
SPKLS to regenerate HSC in the primary transplanted mice
(self-renewal), we transplanted their progeny into secondary
hosts and examined blood lineage regeneration (Figure 4E).
From a cohort transplanted irrespective of CD150 status (shown
in Figure 4A), we selected four lower and four upper SPKLS clones
that showed >1% contribution to all hematopoietic lineages.
Bone marrow from each of these recipients was harvested and
transplanted into four secondary recipients. Of the lower SPKLS
donors, one was a highly myeloid-biased clone (LSP-1,
presumptive CD150+), two were quasibalanced clones (LSP-3
and -4), and onewas a lymphoid-biased clone (LSP-8, presump-
tive CD150). All secondary recipient mice showed engraftment
with clone 1 retaining myeloid-bias, clones 3 and 4 showing a
quasibalanced lineage output, and clone 8 retaining strong
lymphoid skewing. All of the upper SPKLS donors were lymphoid
biased, and all secondary recipient mice showed trilineage
engraftment except for those transplanted with bone marrow
from USP clone 3, only one recipient of which reached our as-
signed threshold for calling successful engraftment of 0.1%
(the other three being just below). Thus, the repopulation
behavior measured in secondary recipients of clonally derived
upper SPKLS cells replicated the lymphoid lineage bias of their
parent clone and were bona fide HSCs.
Aging Changes the Clonal Composition of the HSC
Compartment because of a Relative Expansion
of Myeloid-Biased Lower SPKLS Cells
Our lab and others have shown that aging mouse HSCs show
a decline in long-term reconstituting potential (Chambers et al.,
2007; Rossi et al., 2007) and a deficit in lymphopoiesis (Sudo
et al., 2000; Rossi et al., 2005). However, recent studies suggest
that aging changes the clonal composition of the HSC compart-
ment but does not alter the inherent properties of HSCs (Cho
et al., 2008; Roeder et al., 2008). This implies that the age-related
deficit in lymphopoiesis may not be due to a decline in lymphoidpotential from HSCs, but rather may be due to a relative loss of
lymphoid-biased HSCs over time. Strikingly, in the bone marrow
of old mice, there is an accumulation of lower SP cells in the
region we show to be enriched for myeloid-biased HSCs (Fig-
ure 5A). Competitive transplantation of bulk aged lower and
upper SPKLS was performed to determine whether the lineage
potentials of HSC subtypes is altered with aging.
In agreement with previous studies, aged HSCs were not as
potent as their young counterparts in terms of long-term hema-
topoietic engraftment. However, analysis of the hematopoietic
lineages formed from donor old lower and upper SPKLS cells
mirrored that of young lower and upper SPKLS cells in both
primary and secondary recipients (Figures 5B and 5C). Old lower
SPKLS had significantly greater myeloid potential (32.9% ± 9.8%
versus 2.6% ± 0.9% 16 weeks posttransplant in secondary
recipients) whereas upper SPKLS showed greater propensity
for lymphoid generation in terms of B cells at short-term time
points (32.1% ± 12.7% versus 2.0% ± 0.9% 4 weeks posttrans-
plant in primary recipients) and T cells at long-term time points
(49.8% ± 9.9% versus 11.5% ± 2.1% 16 weeks posttransplant
in secondary recipients). As with transplanted young SP frac-
tions, old donor lower SPKLS cells contributed more to LT-HSC,
MPP, andmyeloid progenitor compartments in the bonemarrow
of primary recipients (Table S1) whereas old donor upper SPKLS
cells produced significantly more CLPs (22.1% ± 6.1% versus
3.3% ± 0.5%).
These data argue that aging does not alter the inherent lineage
potential of individual HSCs, but rather the myeloid bias seen in
aging HSCs is due to a relative expansion of the myeloid-biased
lower SPKLS subpopulation. This shift in proportion can explain
all of the observations of myeloid lineage bias in aging HSCs
from previous reports that were based on testing the entire
HSC population. Because the lineage outputs of SP subtypes
are stable upon rounds of serial transplantation and in aging
mice, lower SPKLS cells will henceforth be called myeloid-biased
HSCs (My-HSCs) and upper SPKLS cells will be called lymphoid-
biased HSCs (Ly-HSCs).
Ly-HSCs Are More Proliferative HSCs
In order to gain insight into molecular mechanisms underlying
the functional biases of HSC subtypes, we globally compared
the gene expression profiles of My-HSCs and Ly-HSCs (Table
S2). We identified 785 genes that were differentially expressed
between My-HSCs and Ly-HSCs, with 434 higher in My-HSCs
(Table S3) and 351 higher in Ly-HSCs (Table S4). The expression
of a subset of the most significant differentially expressed genes
were analyzed by real-time PCR on independently isolated
samples (Figures S4A and S4B), demonstrating excellent
corroboration of microarray data.
Ingenuity Pathway Analysis (IPA) revealed that Ly-HSCs
expressed many genes reflective of highly activated cells; 9 of
the 12 pathways significantly enriched in Ly-HSCs were related
to cell cycle or metabolism (Figure S4C). A higher rate of turnover
of Ly-HSCs compared to My-HSCs may lead to earlier exhaus-
tion of this HSC subtype over the lifetime of the animal, perhaps
consistent with the proportional change in HSC subtypes with
age. Analysis of the cell cycle status of lower and upper SPKLS
cells via PI staining, BrdU labeling, Hoechst/Pyronin Y staining,
and Ki67 staining (Figure S5) showed that Ly-HSCs are moreCell Stem Cell 6, 265–278, March 5, 2010 ª2010 Elsevier Inc. 271
Figure 5. Aging SP Subtypes Retain Lineage Differen-
tiation Biases
(A) Contour plot comparisons of young (10-week-old) and old
(90-week-old) SPs showing an accumulation of lower SP cells
in aged mice.
(B) Overall peripheral blood contribution (Engraft) and propor-
tional contribution to myeloid, B, and T cells at 4 and 16 weeks
after transplantation of old and young SP fractions.
(C) Peripheral blood contribution after secondary transplanta-
tion from recipients of aged lower and upper SPKLS cells.
Error bars represent SEM.
Cell Stem Cell
Hematopoietic Stem Cell Heterogeneityproliferative while My-HSCs are more quiescent, both at any
given point in time and over given time frames.
TGF-b1 Elicits Different Responses
from HSC Subtypes In Vitro
Gene ontology analysis (GO; Ogata et al., 1999) showed that one
of the fewmolecular pathways significantly enriched inMy-HSCs
was the TGF-b signaling pathway. TGF-b signaling has been
implicated in the regulation of HSC quiescence (Yamazaki
et al., 2009), and TGF-b signaling-deficient HSCs have increased
proliferative capacity in vitro, although in vivo HSC quiescence
and maintenance of the HSC pool is not dependent on TGF-b
signaling (Larsson et al., 2003, 2005). HSCs have also been
shown to have a biphasic response to TGF-b stimulation, with
high concentrations being inhibitory and low concentrations
stimulatory (Kale, 2004; Kale and Vaidya, 2004). These appar-
ently contradictory responses of HSC to TGF-b signaling led
us to hypothesize that TGF-b may exert different effects on
My- and Ly-HSC subtypes.
To test this, we subjected My- and Ly-HSCs to TGF-b1, -2,
and -3 in a variety of assays to determine the effects of these272 Cell Stem Cell 6, 265–278, March 5, 2010 ª2010 Elsevier Inc.growth factors on HSC subtypes. To summarize
a number of experiments (Figure S6), we found
high concentrations of all TGF-bs (10 ng/mL) was
inhibitory to for both My- and Ly-HSCs in vitro;
however, at lower concentrations of TGF-bs (10
pg/mL), we found TGF-b1, -2, and -3 to be stimula-
tory for My-HSCs, whereas TGF-b1 and -2 were
inhibitory to Ly-HSC (TGF-b3 was in general stimu-
latory for Ly-HSCs). Because the biggest distinc-
tions in HSC subtype response were produced by
exposure to TGF-b1, we focused on this factor
for more detailed analysis.
We first tested the effect of TGF-b1 on HSC
subtypes by colony formation assays in Methocult
medium supplemented with TGF-b1 (Figure 6A).
Exposure ofMy-HSCs toexogenous TGF-b1accel-
erated initial colony formation (7 days), although the
total number of colonies scored after 15 days was
not different. This initial difference was due to the
more rapid appearance of CFU-GM colonies rela-
tive to control My-HSCs. Conversely, exogenous
TGF-b1 impeded colony formation of Ly-HSCs
throughout the time course, because of the inhibi-
tion of CFU-GM colony differentiation. The size of
multilineage CFU-GEMM colonies produced byMy-HSCs in response to TGF-b1 was also greater compared to
controls (Figure 6B), and flow cytometric analysis determined
that this was not due to overrepresentation of a specific cell
type (Figure S6C). Thus TGF-b1 appears to be a general stimula-
tory factor for My-HSC proliferation.
This differential effect of TGF-b1 could be due to enhancing
proliferation, or differentiation, because both properties impact
the outcome of methycellulose assays. To exclusively examine
the effect on HSC proliferation over a shorter time frame,
My- and Ly-HSCs were purified and incubated with 10 pg/mL
TGF-b1 for 5 hr and then subjected to Pyronin Y staining, which
allows the proportion of HSC exiting G0 to be determined
(Figure 6C). My-HSCs engaged the cell cycle after stimulation
with TGF-b1, with a smaller proportion of cells, relative to
controls, remaining in G0 after the incubation. In contrast, exit
from G0 by Ly-HSCs was impeded by TGF-b1.
TGF-b1 Promotes Proliferation and Myeloid
Differentiation Specifically in My-HSCs
To determine whether exogenous TGF-b1 could also affect
HSCs in vivo, groups of mice were injected with 0.1 mg TGF-b1
Figure 6. HSC Subtypes Show Differential
Responses to TGF-b1
(A) Low (10 pg/mL) concentrations of TGF-b1 accelerated
colony formation of My-HSCs (more colonies at day 7),
but did not change the total number of colonies formed
(at day 15), whereas TGF-b1 proved inhibitory to Ly-HSC
colony formation. The lines indicate the total number of
colonies per plate, and the bar graphs represent the
number of CFU-GM colonies at each time point. Data
presented are cumulative of four individual experiments,
each comprising two replicate plates for each condition.
(B) The CFU-GEMM colonies from My-HSCs in the pres-
ence of TGF-b1 were markedly larger in size than control
colonies.
(C) Analysis of Pyronin Y staining ofMy- and Ly-HSCs after
5 hr in vitro exposure to TGF-b1. Data are averages of
three separate experiments.
(D) BrdU uptake after in vivo TGF-b1 exposure by progeny
of transplanted My- and Ly-HSCs. In analyzing the
progeny of transplanted HSCs, CD150 expression was
used as a surrogate marker for myeloid-biased (CD150+)
and lymphoid-biased (CD150) daughter HSCs.
(E) Real-time PCR analysis of purified My- and Ly-HSCs
after 5 hr in vitro TGF-b1 exposure.
Data presented are averages for three separate experi-
ments. Error bars represent SEM. Asterisks indicate the
genes that exhibit statistically significant differences in
response between My- and Ly-HSCs (see also Figures
S5–S7).
Cell Stem Cell
Hematopoietic Stem Cell Heterogeneity(Grzegorzewski et al., 1994) and then injected with BrdU to label
HSCs that entered S phase during the 12 hr BrdU exposure
period. My- and Ly-HSCs were then purified and analyzed for
BrdU incorporation (Figure S6E). Consistent with the in vitro
studies, exposure to TGF-b1 produced a subtle yet significantCell Stem Cell 6,stimulatory effect onMy-HSC proliferation while
inhibiting turnover of Ly-HSCs.
In order to more accurately assess the in vivo
response of HSC subtypes to TGF-b1, we trans-
planted a cohort of CD45.1/2 mice with limiting
number of My-HSCs (25 CD45.1 lower SPKLS)
and Ly-HSCs (50 CD45.2 upper SPKLS) and
monitored the response of each transplanted
cell population to exogenous TGF-b1 after
stable hematopoietic reconstitution (12 weeks
posttransplant). Test mice were administered
three 0.1 mg TGF-b1 injections 24 hr apart and
then labeled with BrdU 12 hr prior to sacrifice
to determine the effect of TGF-b1 on turnover
rate of donor cell-derived stem and progenitor
cell compartments (Figure 6D; see Figure S7
for gating schemes). TransplantedMy-HSCs re-
sponded to TGF-b1 by showing increased
proliferation of CD150+ HSCs (as a surrogate
marker for myeloid-biased HSCs; CD150+
CD34KLS) and myeloid progenitors, but no
difference in proliferation of CD150 HSCs
(surrogate marker for lymphoid-biased HSCs;
CD150CD34KLS) or CLPs. The proliferation
of transplanted Ly-HSC-derived myeloid pro-genitors was inhibited by exogenous TGF-b1 although no other
significant changes were noted in any stem/progenitor cell
compartment. Thus, TGF-b1 induces a proliferative response
in My-HSCs, acting directly on their daughter HSCs and myeloid
progenitors.265–278, March 5, 2010 ª2010 Elsevier Inc. 273
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in HSC Subtypes
In order to assess the molecular responses of HSC subtypes to
TGF-bs, real-time PCR analysis was conducted on My- and
Ly-HSCs that were exposed to 10 pg/mL TGF-b in vitro for 5 hr
(Figure 6E). Genes for p18 and p19, which inhibit the G0 to G1
transition, were downregulated in My-HSCs exposed to
TGF-b1 and upregulated in Ly-HSCs. No change was observed
in p16 and p21 expression, and inhibitors of the later parts of the
cell cycle such as p57 changed in parallel in My- and Ly-HSCs.
Of the oncogenes that have been proposed to be regulated by
TGF-b, Evi1 showed a strong upregulation in Ly-HSCs in
response to TGF-b1 and slight downregulation in My-HSCs.
Evi1 prevents terminal differentiation of bone marrow progeni-
tors (Buonamici et al., 2003), and thus its upregulation by
Ly-HSCs in response to TGF-b may be one of the mechanisms
behind TGF-b-induced proliferative suppression. Showing the
opposite pattern was c-jun, induced during the G0 to G1 transi-
tion (Cosenza et al., 1994), which became upregulated only in
My-HSCs after TGF-b exposure. Of genes known to be involved
in myeloid or lymphoid differentiation, divergent responses in
PU.1 and Ikaros expression were observed, regulators of my-
eloid and lymphoid differentiation, respectively, with My-HSCs
upregulating PU.1 and Ly-HSCs upregulating Ikaros. This
suggests that TGF-b1 is biasing the stem cells evenmore toward
their intrinsic differentiation fates. No significant differences were
noted in the downstream regulators of TGF-b signaling Smad2,
-3, and -7, although their activation is generally mediated by
protein phosphorylation.
DISCUSSION
The classical model of hematopoietic hierarchy that proposes
that all the mature cells of the peripheral blood are the progeny
of a single LT-HSC, the so-called clonal succession model (Fig-
ure 7A), has come under scrutiny recently as more evidence
accumulates that the HSC pool actually consists of multiple
HSC subtypes with distinct functional potentials. The work pre-
sented here provides further evidence for this clonal diversity
model (Figure 7B), and the combination of SP and CD150 shows
a clear gradient in HSC potential suggesting that a continuum of
HSC is present in the marrow. By competing the subtypes
against each other, we demonstrated that in the presence of
the other subtypes, the HSC subtypes default to perform almost
exclusively their primary function (i.e., their biases are extreme).
This suggests that in vivo, most stem cells may be highly biased
and behave not at all like classically defined multilineage HSCs.
Initial studies that established this concept of biased HSC
subtypes largely arose from analysis of the repopulation kinetics
of mice transplanted with phenotypically identical populations
(Mu¨ller-Sieburg et al., 2002, 2004; Dykstra et al., 2007). Further
understanding of the mechanisms that regulate these HSC
subtypes requires the ability to prospectively isolate them. The
Eaves group recently showed that CD150 could be used to
distinguish myeloid- and lymphoid-biased HSC purified on the
basis of CD45+EPCR+CD48 expression (Kent et al., 2009) and
were able to identify some differentially expressed genes.
Here, we show that Hoechst dye efflux and CD150 reveal
a gradient of HSC self-renewal activity and myeloid bias corre-274 Cell Stem Cell 6, 265–278, March 5, 2010 ª2010 Elsevier Inc.lating with the phenotypes (in order) CD150+lower SPKLS > >
CD150lower SPKLS > > CD150+upper SPKLS > > CD150upper
SPKLS with an opposing gradient of proliferative potential and
lymphoid bias. However, although the average activities of the
clones point to these correlations, there was substantial variation
between individual HSCs. This implies that either the populations
are still a mixture of more functionally distinct cells, or that the SP
actually represents a continuum of HSC activities, which
hampers the absolute segregation of distinct HSC phenotypes
(Figure 7B). Because the peculiar Hoechst staining of the SP
results from differential efflux of the dye by HSCs because of
high multi-drug-resistance (MDR)-type transporter activity
(Goodell et al., 1996; Zhou et al., 2001), it will be interesting to
determine whether the discrete efflux properties will prove to
have biological significance for the HSC subtypes.
Previous studies have shown that aging HSCs have reduced
ability to reconstitute lethally irradiated recipients in transplanta-
tion assays (Morrison et al., 1996; Liang et al., 2005), a vastly
different gene expression profile (Rossi et al., 2005; Chambers
et al., 2007), and amyeloid-differentiation bias compared to their
young counterparts (Sudo et al., 2000; Kim et al., 2003).
However, these studies compared the entire HSC pools from
old versus young mice, not taking into account potential popula-
tion dynamics. One study suggested that the age-related
changes reflect changes in the clonal composition of the HSC
pool of old mice (Cho et al., 2008). Indeed, we observed an
accumulation of lower SPKLS in the bone marrow of old mice,
yet lower and upper SPKLS cells exhibit the same differentiation
bias of their young counterparts. Thus, the apparent myeloid
bias of aging HSCs reflects a higher proportion of My-HSCs in
the HSC pool, rather than alterations in the developmental
potential of HSCs with age. This could be due to differential
responses to the aging cytokine milieu, the higher proliferative
rate of Ly-HSCs that could lead to their exhaustion, and a greater
self-renewal capacity ofMy-HSCs. Clearly, this dramatic propor-
tional shift of these subpopulationswith age has significant impli-
cations for the interpretation of studies that have described
distinct molecular or biological properties of the aged HSC pool.
TGF-b signaling has been implicated in maintaining HSC
quiescence (Fortunel et al., 2000; Chabanon et al., 2008). Here,
TGF-b1 stimulated My-HSCs to proliferate, while proving inhibi-
tory to Ly-HSCs. This appears to be physiological relevant, as
indicated by the fact that increased proliferation of My-HSCs
was apparent in vitro and in vivo. Furthermore, when mice
were cotransplanted with limited numbers of genetically distin-
guishable My- and Ly-HSCs and then administered TGF-b1 after
stable engraftment (Figure 6D), TGF-b1 acted directly on the
transplanted My-HSC population, stimulating the proliferation
of its daughter myeloid-biased HSCs and myeloid progenitors,
while in the same animals simultaneously inhibiting the prolifera-
tion of transplanted Ly-HSC-derived myeloid progenitors. This
highlights the unique responsiveness of distinct HSC subtypes,
and their immediate progeny, to a growth factor and provides a
potential mechanism for differential regulation of HSC subtypes.
One of the molecular mechanisms governing the proliferative
response of My-HSCs to TGF-b1 appears to be downregulation
of theG0 to G1 cell cycle inhibitors p18 and p19. Other differential
responses were detected in HSC subtypes upon exposure to
TGF-bs, most notably the proto-oncogenes Evi1 (upregulated
Figure 7. Model for HSC Clonal Diversity
and Its Relation to the SP Phenotype
(A) The traditional clonal succession model (left) in
which all mature blood cells are the progeny of a
single uniform pool of LT-HSCs, and the clonal
diversity model (right), supported by our data, in
which distinct HSC subtypes are capable of
contributing to all lineages, but are stably pro-
grammed to do so in a highly biased fashion.
(B) The SP allows visual representation of the
continuum of HSC subtypes encompassing the
spectrum from the most myeloid-biased CD150+
lower SPKLS to the most lymphoid-biased CD150
upper SPKLS. The HSC subtypes exhibit additional
cellular, molecular, and functional distinctions. A
parental unbiased HSC probably exists during
development, and conceivably in the adult.
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My- and Ly-HSC subtypes have distinct molecular and cellular
responses to TGF-b signaling, further enforcing their specific
characteristics. It is possible that TGF-b signaling in the bone
marrow niche functions as a ‘‘fine-tuning’’ mechanism for
cross-talk between HSC subtypes to mediate the numbers of
each actively engaged in hematopoiesis at any given point in
time. We also speculate that the proportional increase of the
My-HSC compartment with age could be due in part to differ-
ences in TGF-b ligand production, and the consequent response
particularly of My-HSCs, in the inflammatory setting of an aging
environment.Cell Stem Cell 6, 265–2The My-HSCs exhibit the highest
engraftment rate per mouse when single
cells were transplanted, as well as the
highest overall contribution to peripheral
blood regeneration in each mouse. The
secondary transplant data also suggest
that My-HSCs have higher self-renewal
capacity. It is likely that if the contribution
of the HSC subtypes were examined over
a longer time period (6 to 12 months), we
would see further distinctions in the My-
and Ly-HSCs with regard to their ability
to sustain blood production. While clearly
bona fide HSCs according to the rigorous
criteria imposed here, blood production
from Ly-HSCs may prove less durable,
consistent with their lower potency and
higher proliferative rate. The recent report
of a class of HSCswith intermediate-term
durability underscores this key property
(Benveniste et al., 2010).
This visual continuum of HSCs with
different dye efflux capacity, correlating
with a functional gradient, makes it
tempting to speculate that My-HSCs are
the most primitive, generating the less
primitive, less quiescent Ly-HSC. Al-
though both HSC types clearly have the
potential to generate each other (Fig-ure 3C), each HSC subtype preferentially regenerated itself,
arguing that these HSC pools operate largely independently of
each other. This suggests a deterministic explanation for the
data. Perhaps an omnipotent HSC present during development
(conceivably still present in adult marrow) establishes a consor-
tium of HSCs during seeding of the bone marrow. Their epige-
netic state, or their different niches, may indelibly dictate their
propensity to generate thedownstreamcomponents of theblood
in a biased fashion, as well as their self-renewal capacities. Thus,
the properties of these HSC subtypes suggest a lineal relation-
ship, but that may be a result of the limitations of the current
assays and our historical interpretations.78, March 5, 2010 ª2010 Elsevier Inc. 275
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etic systems can be traced back over 100 years when staining
techniques enabled identification of different white blood cell
lineages. ‘‘Unitarians’’ believed that erythrocytes, granulocytes,
and lymphocytes all came from a cell of common origin whereas
‘‘dualists’’ argued that myeloid and lymphoid cells derived from
committed precursors residing in distinct hematopoietic tissues
(reviewed in Ramalho-Santos and Willenbring, 2007). The
unitarian concept may still hold true, but the mounting evidence
for clonal diversity in the HSC pool with distinct subtypes
dedicated to regenerating particular compartments argues
that revision of the long-held view of a unipotent stem cell pool
generating the entire branching hematopoietic differentiation
tree must come under scrutiny. The clonal diversity model has
important implications for experimental and clinical HSC biology
including the selection of appropriate HSC subtypes for trans-
plantation or cell/gene therapy applications, the incidence of
myeloproliferative disorders in the elderly, and the cellular and
behavioral heterogeneity seen in genetically similar leukemias.
Here we prospectively isolate functionally distinct HSC subtypes
and provide mechanistic insight into the molecular regulation of
myeloid- and lymphoid-biased HSC function.
EXPERIMENTAL PROCEDURES
Mice and Hematopoietic Stem Cell Purification
All animal procedures were IUCAC approved and conducted in accordance
institutional guidelines. Mice were housed in a specific-pathogen-free facility
and fed autoclaved acidified water and mouse chow ad libitum. All mice
were C57Bl/6 background distinguished by CD45.1 or CD45.1 alleles. Whole
bone marrow (WBM) was isolated from femurs and tibias, and SP cell staining
was performed with Hoechst 33342 (Sigma-Aldrich) as previously reported
(Goodell et al., 1996). WBMwas resuspended in stainingmedia at 106 cells/mL
and incubated with 5 mg/mL Hoechst 33342 for 90 min at 37C. For antibody
staining, cells were suspended at a concentration of 108 cells/mL and incu-
bated on ice for 20min with various combinations of antibodies (Supplemental
Experimental Procedures). Cell sorting was performed on a MoFlo cell sorter
(Coulter) and analysis on an LSRII (BD Biosciences).
Transplantation and Peripheral Blood Analysis
After a split dose of 10.5 Gy of irradiation, recipients were transplanted by
intravenous injection. Donor HSCs were competed against 2 3 105 unfractio-
nated WBM cells with the opposite CD45 allele (matched to the recipient).
For peripheral blood analysis, mice were bled retro-orbitally, the red blood
cells were lysed, and each sample was incubated with the following antibodies
on ice for 20 min: CD45.1-FITC, CD45.2-APC, CD4-Pacific Blue, CD8-Pacific
Blue, B220-Pacific Blue, B220-PeCy7, Mac1-PeCy7, and Gr-1-PeCy7 as
previously described (Challen et al., 2009). Cells were then spun down and
resuspended in a propidium iodide solution, and analysis was accomplished
on live cells with an LSRII (Becton Dickinson). For secondary transplantation
from mice transplanted with bulk lower and upper SPKLS cells, WBM was
isolated >18 weeks after transplantation and SPKLS were purified, also sorting
on the CD45 allele of the original donor SPKLS cells. 200 of these purified HSCs
were competed against 2 3 105 fresh WBM cells.
Hematopoietic Progenitor Cell Analysis of Transplanted Mice
More than eighteen weeks after transplantation, recipient mice were sacri-
ficed, and bone marrow was isolated and analyzed with antibody schemes
to identify the donor-derived multipotent progenitor (MPP; Lineage Sca-1+
c-Kit+ Flk-2+), myeloid progenitor (MP; Lineage Il7ra Sca-1 c-Kit+), and
common lymphoid progenitor (CLP; Lineage Il7ra+ Sca-1+ c-Kit+) compart-
ments as previously described (Akashi et al., 2000; Kondo et al., 1997).
Single-Cell Transplantation
Compromised competitorWBMwasderivedby transplanting lethally irradiated
CD45.1 mice with 1 3 106 CD45.1 WBM cells and harvesting the WBM 12276 Cell Stem Cell 6, 265–278, March 5, 2010 ª2010 Elsevier Inc.weeksposttransplant. 13106 compromisedWBMcellswere seeded intowells
of a 96-well plate, and single CD45.2 test HSCs were sorted directly into the
wells. For secondary transplantation, WBMwas harvested from each recipient
and one femur equivalent was divided into four secondary CD45.1 hosts.
Methocult Assays
Single HSCs were sorted into 96-well plates containing Methocult 3434
medium (Stem Cell Technologies supplemented with penicillin/streptomycin
and cultured in vitro at 37C for 2 weeks unless stated otherwise.
Microarray Analysis
Lower and upper SPKLS cells were sorted from three pools of 24 mice
(10-week-old male CD45.1 C57Bl/6) on separate days, yielding 12,000–
16,000 HSCs for each of three biological replicates. Purity of each sort was
>98%. RNA was isolated with the RNAqueous (Ambion), treated with DNase
I, and precipitated with phenol:chloroform:isoamyl alcohol. The RNA was line-
arly amplified (Venezia et al., 2004) in two rounds of T7 in vitro transcription
(MessageAmp, Ambion) and labeled with biotin-UTP and -CTP (Enzo Biotech)
during the second amplification. Labeled RNA (20 mg) was diluted in fragmen-
tation buffer, incubated at 94C for 25 min, and hybridized to Affymetrix
MOE430.2 chips according to standard protocols. The raw image and intensity
files were generated with GCOS 1.0 software (Affymetrix). Microarray chips
passed quality control tests, including a scale factor <5, a 50 to 30 probe
ratio <20, a replicate correlation coefficient >0.96, unbiased global clustering
analysis, and limited RNA degradation analyzed with the 50 to 30 signal intensity
ratios from chip probes. Normalization andmodel-based expressionmeasure-
ments were performed with GC-RMA (http://www.bioconductor.org; http://
cran.r-project.org/). Determination of differentially expressed genes between
samples was defined as fold-change > 2, adjusted p value < 0.05, B-statistic
> 0. Microarray data were further analyzed with Ingenuity Pathways Analysis
(Ingenuity Systems).
Real-Time PCR Analysis
RNA was isolated with RNAqueous from FACS-sorted cells isolated indepen-
dently from the samples used for microarray analysis. RNA was reverse
transcribed with random hexamer primers with Super Script II (Invitrogen).
cDNA input was standardized and RT-PCRs were performed with Taqman
master Mix (Applied Biosystems), 18 s-rRNA probe (VIC-MGB; Applied
Biosystems), and a gene-specific probe (FAM-MGB; Applied Biosystems)
for 50 cycles with an AbiPrism 7900HT (Applied Biosystems). Samples were
normalized to 18S and fold-change determined by the DDCt method.
TGF-b
Recombinant TGF-bs (R&D Systems) were reconstituted according to the
manufacturer’s recommendations and assayed at the stated concentrations.
Cell Cycle Analysis of Transplanted HSC Progeny
Mice received one intraperitoneal injection of BrdU (Sigma-Aldrich; 1 mg/6 g of
mouse weight) and sacrificed 12 hr later. WBM was stained with antibodies to
identify stem and progenitor cell compartments (Figure S7) and then prepared
for analysis ofBrdU incorporationwith theFITC-BrdUFlowKit (BDPharMingen).
Pyronin Y Staining
200,000 B220-FITC+ carrier splenocytes were presorted into collection tubes.
HSCs (more than 1000) were then sorted into the same tube. After TGF-b1
incubation, cells were then incubated for 45 min with 20 mg/mL Hoechst
33342 and 50 mg/mL Verapamil (Sigma-Aldrich) in phosphate-buffered saline
supplemented with 3% fetal bovine serum. Pyronin Y (Sigma-Aldrich) was
then added at 1 mg/ml, and the cells were incubated for another 15 min at
37C, washed, and immediately analyzed on a BD LSRII. During flow analysis,
both Hoechst 33342 and Pyronin Y signal were displayed under linear mode.
The carrier B cells were then a control to define the G0/G1 DNA content.
Statistics
Student’s t test and 1-way ANOVAs were used for statistical comparisons
where appropriate. Significance is indicated on the figures with the following
convention: *p < 0.05, **p < 0.01, ***p < 0.001. Error bars on all graphs repre-
sent the SEM.
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Data can be found in Gene Expression Omnibus (accession GSE16475).
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